Case report: Cerebral sinus vein thrombosis in VEXAS syndrome
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a newly described hemato-inflammatory acquired monogenic entity that presents in adulthood. One of the main features of VEXAS syndrome is a high venous thromboembolism (VTE) burden, with approximately 30–40% experiencing lower extremity deep vein thrombosis and a lower incidence of pulmonary embolism at approximately 10%. To date, VEXAS syndrome has not been associated with rarer forms of VTE such as cerebral sinus vein thrombosis (CSVT) and Budd–Chiari syndrome, which are well-recognized vascular manifestations in Behcet’s disease, another autoinflammatory vasculitic disease. Herein, we describe a case of acute severe extensive and fatal CSVT in a patient with VEXAS syndrome. The event occurred during a period of apparently quiescent inflammatory status, while the patient was receiving tocilizumab and a low dose of glucocorticoids. Despite treatment with anticoagulation, high-dose glucocorticoids, endovascular thrombectomy, and intracranial pressure-lowering agents, the patient suffered severe neurologic damage and ultimately succumbed to the condition 3 weeks after the onset of CSVT. To the best of our knowledge, this is the first reported case of CVST in a patient with VEXAS syndrome..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Medicine - 11(2024) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michael Zisapel [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Autoinflammatory disease |
|---|
| doi: |
10.3389/fmed.2024.1377768 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ092534619 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ092534619 | ||
| 003 | DE-627 | ||
| 005 | 20240412125807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2024.1377768 |2 doi | |
| 035 | |a (DE-627)DOAJ092534619 | ||
| 035 | |a (DE-599)DOAJe4cce028b57c465cbd21f3ea5bebabb9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Michael Zisapel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case report: Cerebral sinus vein thrombosis in VEXAS syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a newly described hemato-inflammatory acquired monogenic entity that presents in adulthood. One of the main features of VEXAS syndrome is a high venous thromboembolism (VTE) burden, with approximately 30–40% experiencing lower extremity deep vein thrombosis and a lower incidence of pulmonary embolism at approximately 10%. To date, VEXAS syndrome has not been associated with rarer forms of VTE such as cerebral sinus vein thrombosis (CSVT) and Budd–Chiari syndrome, which are well-recognized vascular manifestations in Behcet’s disease, another autoinflammatory vasculitic disease. Herein, we describe a case of acute severe extensive and fatal CSVT in a patient with VEXAS syndrome. The event occurred during a period of apparently quiescent inflammatory status, while the patient was receiving tocilizumab and a low dose of glucocorticoids. Despite treatment with anticoagulation, high-dose glucocorticoids, endovascular thrombectomy, and intracranial pressure-lowering agents, the patient suffered severe neurologic damage and ultimately succumbed to the condition 3 weeks after the onset of CSVT. To the best of our knowledge, this is the first reported case of CVST in a patient with VEXAS syndrome. | ||
| 650 | 4 | |a VEAXS syndrome | |
| 650 | 4 | |a cerebral sinus vein thrombosis | |
| 650 | 4 | |a venous thromboembolism | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a autoinflammatory disease | |
| 650 | 4 | |a tocilizumab (IL-6 inhibitor) | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Michael Zisapel |e verfasserin |4 aut | |
| 700 | 0 | |a Estelle Seyman |e verfasserin |4 aut | |
| 700 | 0 | |a Jeremy Molad |e verfasserin |4 aut | |
| 700 | 0 | |a Jeremy Molad |e verfasserin |4 aut | |
| 700 | 0 | |a Hen Hallevi |e verfasserin |4 aut | |
| 700 | 0 | |a Hen Hallevi |e verfasserin |4 aut | |
| 700 | 0 | |a Michal Mauda-Havakuk |e verfasserin |4 aut | |
| 700 | 0 | |a Michal Mauda-Havakuk |e verfasserin |4 aut | |
| 700 | 0 | |a Tali Jonas-Kimchi |e verfasserin |4 aut | |
| 700 | 0 | |a Tali Jonas-Kimchi |e verfasserin |4 aut | |
| 700 | 0 | |a Ori Elkayam |e verfasserin |4 aut | |
| 700 | 0 | |a Ori Elkayam |e verfasserin |4 aut | |
| 700 | 0 | |a Tali Eviatar |e verfasserin |4 aut | |
| 700 | 0 | |a Tali Eviatar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Medicine |d Frontiers Media S.A., 2014 |g 11(2024) |w (DE-627)DOAJ000022292 |x 2296858X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2024.1377768 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e4cce028b57c465cbd21f3ea5bebabb9 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmed.2024.1377768/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2296-858X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 | ||